Showing results (1-10 of 3) with videos related to
Sort By:
Pageof 1
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.Pageof 1